ArticleGene therapy2007
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Article in Gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation.Frontiers in oncology · 2026Review
- Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects.Journal of clinical medicine · 2022Review
- Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective.Oxidative medicine and cellular longevity · 2022Review
- A brief review of reporter gene imaging in oncolytic virotherapy and gene therapy.Molecular therapy oncolytics · 2021Review
- Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.Molecular therapy oncolytics · 2019Review
- Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging.Scientific reports · 2017Article
- Monitoring the Efficacy of Oncolytic VirusesFrontiers in oncology · 2017Review
- The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.Cancer gene therapy · 2013Article
- Oncolytic virotherapy: the questions and the promise.Oncolytic virotherapy · 2013Review
- Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.Virology journal · 2010Article
- Evaluation of adenovirus capsid labeling versus transgene expression.Virology journal · 2010Article
- Armed replicating adenoviruses for cancer virotherapy.Cancer gene therapy · 2009Review
- Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.Cancer gene therapy · 2008Article
- Reporter Transgenes for Monitoring the Antitumor Efficacy of Recombinant Oncolytic Viruses.Acta naturaeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic viruses kill cancer cells by tumor-selective replication. Clinical data have established the safety of the approach but also the need of improvements in potency. Efficacy of oncolysis is linked to effective infection of target cells and subsequent productive replication. Other variables include intratumoral barriers, access to target cells, uptake by non-target organs and immune response. Each of these aspects relates to the location and degree of virus replication. Unfortunately, detection of in vivo replication has been difficult, labor intensive and costly and therefore not much studied. We hypothesized that by coinfection of a luciferase expressing E1-deleted virus with an oncolytic virus, both viruses would replicate when present in the same cell. Photon emission due to conversion of D-Luciferin is sensitive and penetrates tissues well. Importantly, killing of animals is not required and each animal can be imaged repeatedly. Two different murine xenograft models were used and intratumoral coinjections of luciferase encoding virus were performed with eight different oncolytic adenoviruses. In both models, we found significant correlation between photon emission and infectious virus production. This suggests that the system can be used for non-invasive quantitation of the amplitude, persistence and dynamics of oncolytic virus replication in vivo, which could be helpful for the development of more effective and safe agents.
Indexed as
Identifiers
17377596What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.